26 May 2017

Appointment of Joint Broker


London, UK, 26 May 2017: Shield Therapeutics plc (LSE:STX), a speciality pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, today announces that it has appointed Peel Hunt LLP to act as its Joint Broker with immediate effect to act alongside Liberum Capital Limited, who will continue to act as Nominated Adviser and Joint Broker to Shield.





For further information please contact:


Shield Therapeutics plc

+44 (0) 20 7467 6920

Carl Sterritt, Chief Executive Officer

Joanne Estell, Chief Financial Officer


Nominated Adviser and Joint Broker

+44 (0)20 3100 2222

Liberum Capital Limited


Christopher Britton/Steve Pearce


Joint Broker                                                                                                 

+ 44 (0)20 7418 8900

Peel Hunt LLP


James Steel/Dr. Christopher Golden



Financial PR Advisor

+44 (0)203 709 5700

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal




About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com

Back to previous page